Compare APRE & REED Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | APRE | REED |
|---|---|---|
| Founded | 2006 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.8M | 9.1M |
| IPO Year | 2019 | 2009 |
| Metric | APRE | REED |
|---|---|---|
| Price | $0.59 | $0.64 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $3.73 | N/A |
| AVG Volume (30 Days) | ★ 216.9K | 142.8K |
| Earning Date | 11-11-2026 | 08-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 21.22 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $34,065,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $27.29 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.55 | $0.56 |
| 52 Week High | $1.69 | $5.97 |
| Indicator | APRE | REED |
|---|---|---|
| Relative Strength Index (RSI) | 31.60 | 38.60 |
| Support Level | N/A | $0.63 |
| Resistance Level | $0.81 | $0.94 |
| Average True Range (ATR) | 0.06 | 0.06 |
| MACD | -0.02 | 0.01 |
| Stochastic Oscillator | 12.15 | 45.25 |
Aprea Therapeutics Inc is a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients with biomarker-defined cancers. It develops small molecule inhibitors designed to exploit genetic mutations in cancer to widen the therapeutic window and is intended to make treatments more effective at destroying cancer cells while sparing healthy tissue. The company's pipeline of clinical and preclinical programs includes APR-1051, a WEE1 inhibitor; ATRN-119 (Mosipasertib), an oral small molecule inhibitor of ataxia telangiectasia and Rad3-related, or ATR; and an early-stage program, APR-1602. These candidates are being developed for broad applications in cancer treatment.
Reed's Inc is a branded beverage company offering a portfolio of natural, premium, and functional beverages under the Reed's and Virgil's brands. The company's portfolio of handcrafted, all-natural beverages is sold in outlets nationwide, including the natural and specialty food channel, grocery stores, mass merchants, drug stores, convenience stores, club stores, and on-premise locations, including bars and restaurants. The company operates in a single reportable segment, which consists of manufacturing carbonated beverages under Reed's and Virgil's brand names.